[go: up one dir, main page]

CA2377397A1 - Antagonistes de recepteurs de il-8 - Google Patents

Antagonistes de recepteurs de il-8 Download PDF

Info

Publication number
CA2377397A1
CA2377397A1 CA002377397A CA2377397A CA2377397A1 CA 2377397 A1 CA2377397 A1 CA 2377397A1 CA 002377397 A CA002377397 A CA 002377397A CA 2377397 A CA2377397 A CA 2377397A CA 2377397 A1 CA2377397 A1 CA 2377397A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
4alkyl
heterocyclic
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002377397A
Other languages
English (en)
Inventor
Deborah L. Bryan
John G. Gleason
Katherine L. Widdowson
Gregory M. Benson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2377397A1 publication Critical patent/CA2377397A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nouveaux composés de formule (I), compositions pharmaceutiques les contenant et leur utilisation pour traiter des états pathologiques induits par une chimiokine, l'interleukine-8 (IL-8).
CA002377397A 1999-06-16 2000-06-16 Antagonistes de recepteurs de il-8 Abandoned CA2377397A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967499P 1999-06-16 1999-06-16
US60/139,674 1999-06-16
PCT/US2000/016813 WO2000076516A1 (fr) 1999-06-16 2000-06-16 Antagonistes de recepteurs de il-8

Publications (1)

Publication Number Publication Date
CA2377397A1 true CA2377397A1 (fr) 2000-12-21

Family

ID=22487784

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377397A Abandoned CA2377397A1 (fr) 1999-06-16 2000-06-16 Antagonistes de recepteurs de il-8

Country Status (22)

Country Link
EP (1) EP1191934A4 (fr)
JP (1) JP2003501471A (fr)
KR (1) KR20020009635A (fr)
CN (1) CN1494424A (fr)
AR (1) AR029368A1 (fr)
AU (1) AU766086B2 (fr)
BR (1) BR0010985A (fr)
CA (1) CA2377397A1 (fr)
CZ (1) CZ20014490A3 (fr)
EC (2) ECSP003525A (fr)
HK (1) HK1044716A1 (fr)
HU (1) HUP0202019A3 (fr)
IL (1) IL146214A0 (fr)
MX (1) MXPA01013287A (fr)
NO (1) NO20016065D0 (fr)
NZ (1) NZ515232A (fr)
PE (1) PE20010319A1 (fr)
PL (1) PL352218A1 (fr)
TR (1) TR200103690T2 (fr)
UY (1) UY26209A1 (fr)
WO (1) WO2000076516A1 (fr)
ZA (1) ZA200110203B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE98223T1 (de) * 1988-03-30 1993-12-15 Warner Lambert Co N-(((2,6-disubstituierte)phenyl>n'- arylalkyl> harnstoffe als antihypercholesterolemische und antiatherosclerotische mittel.
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.

Also Published As

Publication number Publication date
AU766086B2 (en) 2003-10-09
TR200103690T2 (tr) 2002-05-21
IL146214A0 (en) 2002-07-25
NO20016065L (no) 2001-12-12
NO20016065D0 (no) 2001-12-12
EP1191934A1 (fr) 2002-04-03
ZA200110203B (en) 2002-09-11
KR20020009635A (ko) 2002-02-01
HK1044716A1 (zh) 2002-11-01
HUP0202019A3 (en) 2003-03-28
PE20010319A1 (es) 2001-05-24
MXPA01013287A (es) 2002-06-04
AR029368A1 (es) 2003-06-25
CN1494424A (zh) 2004-05-05
PL352218A1 (en) 2003-08-11
BR0010985A (pt) 2002-03-26
ECSP003525A (es) 2002-01-25
AU5748200A (en) 2001-01-02
HUP0202019A2 (en) 2002-10-28
EP1191934A4 (fr) 2004-02-04
CZ20014490A3 (cs) 2002-07-17
UY26209A1 (es) 2000-12-29
WO2000076516A1 (fr) 2000-12-21
JP2003501471A (ja) 2003-01-14
ECSP003528A (es) 2002-01-25
NZ515232A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
AU723816B2 (en) IL-8 receptor antagonists
US6271261B1 (en) IL-8 receptor antagonists
US6133319A (en) IL-8 receptor antagonists
US6218539B1 (en) IL-8 receptor antagonists
WO1997049399A1 (fr) Antagonistes des recepteurs d'il-8
EP0920417A1 (fr) Antagonistes du recepteur de l'il-8
AU729893B2 (en) IL-8 receptor antagonists
US6335352B1 (en) IL-8 receptor antagonists
WO1998006398A1 (fr) Antagonistes du recepteur il-8
EP0957907A1 (fr) Antagonistes du recepteur de l'il-8
EP0920253A1 (fr) Antagonistes du recepteur il-8
WO2000076457A2 (fr) Antagonistes du recepteur il-8
WO1997049287A1 (fr) Antagonistes des recepteurs d'il-8
AU766086B2 (en) IL-8 receptor antagonists
WO1998005328A1 (fr) Antagonistes du recepteur d'il-8
WO2000076517A1 (fr) Antagonistes des recepteurs de il-8
WO2000073282A1 (fr) Antagonistes du recepteur d'il-8
WO2000076508A1 (fr) Recepteurs antagonistes il-8
WO2000069435A1 (fr) Antagonistes de recepteur il-8
HUP9903949A2 (hu) IL-8 receptor antagonisták

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued